Assessing Bausch Health Companies (NYSE:BHC) Valuation Following OraPharma’s Expansion Into Canada and Puerto Rico

Bausch Health Companies (NYSE:BHC) has announced the commercial expansion of its OraPharma business into Canada and Puerto Rico. By entering these markets, the company aims to broaden access to periodontal disease treatments and foster new partnerships.

See our latest analysis for Bausch Health Companies.

Despite Bausch Health Companies’ big move to expand its OraPharma dental products into Canada and Puerto Rico, investors have seen mixed signals. The stock has posted a 3.8% one-month share price gain, but momentum has faded with a -21.7% return over the past 90 days and a tough -25.9% total shareholder return in the past year. This shows that confidence is still being tested even as management targets new growth markets.

If you’re curious to see what other healthcare names are showing potential, our healthcare stock screener features a wide range of companies with innovative treatments and steady momentum. See the full list for free.

With shares still well below analyst price targets despite fresh expansion plans, investors are left to wonder whether Bausch Health Companies is trading at a bargain or if the market has already accounted for any future rebound.

Most Popular Narrative: 11% Undervalued

Bausch Health Companies’ last close of $6.28 sits below the narrative fair value of $7.08, suggesting opportunity remains if the company can execute on growth. The most widely followed narrative weighs future product launches and ongoing diversification efforts against persistent risks, painting a mixed but cautiously optimistic outlook.

International diversification, with sustained double-digit growth in regions like EMEA and Canada and new product launches in Latin America and Poland, enables Bausch to benefit from expanding healthcare access in emerging markets. This supports long-term topline growth and reduces geographic concentration risk.

Read the complete narrative.

Want to know the quantitative engine powering this valuation? The narrative hinges on ambitious international expansion and margin-positive new product launches, plus pivotal assumptions about earnings growth and future profitability. Find out what makes these projections so compelling and why the consensus sets its sights above the current price. Details are revealed inside the full breakdown.

Result: Fair Value of $7.08 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, significant risks remain, including potential Xifaxan price cuts and the company's heavy reliance on just a few key products for revenue growth.

Find out about the key risks to this Bausch Health Companies narrative.

Build Your Own Bausch Health Companies Narrative

If you’d rather see the figures for yourself or want a different perspective, you can quickly build your own take on Bausch Health Companies, all in under three minutes. Do it your way

A great starting point for your Bausch Health Companies research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Don’t let great opportunities pass you by. Put yourself ahead of the curve and unlock fresh stock picks that could shape your investment journey.

• Tap into high yield potential by accessing these 16 dividend stocks with yields > 3%, offering strong payouts with attractive yields above 3%.
• Spot tomorrow’s artificial intelligence leaders by checking out these 25 AI penny stocks, which is packed with companies at the forefront of the AI revolution.
• Seize value before the crowd by reviewing these 894 undervalued stocks based on cash flows, identified by robust cash flow fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com